| Study characteristics |
| Methods |
Double‐blind, randomized, placebo‐controlled |
| Participants |
Elective on‐pump CABG only |
| Interventions |
Atenolol vs. placebo |
| Outcomes |
SVA |
| Follow‐Up |
8 days |
| Concurrent Antiarrhythmic Medications |
None |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Randomization methods not described |
| Allocation concealment (selection bias) |
Unclear risk |
Concealment methods not described |
| Blinding of participants and personnel (performance bias)
All outcomes |
Low risk |
Double‐blind |
| Blinding of outcome assessment (detection bias)
All outcomes |
Low risk |
Double‐blind |
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
Not addressed |
| Selective reporting (reporting bias) |
Unclear risk |
Protocol not available |
| Intention‐to‐treat analysis |
Unclear risk |
Not reported |
